Explore Survodutide dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Survodutide (BI 456906) is a GLP-1 and glucagon receptor dual agonist developed by Boehringer Ingelheim and Zealand Pharma, studied in obesity and in metabolic dysfunction-associated steatohepatitis (MASH), where the glucagon arm is thought to add direct effects on liver fat and energy expenditure beyond GLP-1-driven appetite suppression. This data shows the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting Survodutide.
13 Survodutide reconstitution calculations have been logged by the WPA community. The most common dose entered is 600mcg (3 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (11 sessions). The most common dosing frequency is once weekly (3 logged protocols).
World Peptide Association aggregates anonymized peptide calculator data to show real-world dosing trends, reconstitution volumes, and vial size preferences across the research peptide community.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.